Rosiglitazone decreases postprandial production of acylation stimulating protein in type 2 diabetics

BACKGROUND: We evaluated plasma ASP and its precursor C3 in type 2 diabetic men with/without rosiglitazone (ROSI) treatment compared to healthy non-obese men. We tested (1) whether plasma ASP or C3 are altered postprandially in subcutaneous adipose tissue or forearm muscle effluent assessed by arter...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahiri, Youssef, Karpe, Fredrik, Tan, Garry D, Cianflone, Katherine
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1876462/
https://www.ncbi.nlm.nih.gov/pubmed/17490487
http://dx.doi.org/10.1186/1743-7075-4-11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1876462/
https://www.ncbi.nlm.nih.gov/pubmed/17490487
http://dx.doi.org/10.1186/1743-7075-4-11

Ejemplares similares